Alpha Cognition Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACOGF research report →
About the company
Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for severe neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its developmental pipeline features ALPHA-1062, an acetylcholine esterase inhibitor designed to address dementia of the Alzheimer's type and mild traumatic brain injury.
- CEO
- Michael E. McFadden
- IPO
- 2021
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $35.66M
- P/E
- -39.22
- P/S
- 0.00
- P/B
- -114.63
- EV/EBITDA
- -3.66
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 456.59%
- ROIC
- -926.43%
- Revenue
- $0 · 0.00%
- Net Income
- $-13,772,567 · -13.68%
- EPS
- $-0.15 · 16.67%
- Op Income
- $-9,705,601
- FCF YoY
- 5.60%
- 52W High
- $5.72
- 52W Low
- $5.72
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.29
- Avg Volume
- 0
Get TickerSpark's AI analysis on ACOGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ACOGF coverage
Recent articles, reports, and earnings notes.
No research on ACOGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACOGF report →Similar companies
Peers in the same neighborhood.